Dirk Scharn - NUVISAN Pharma Services

基本信息

Career Trajectory

Bio

Dirk Scharn currently works at the Drug Metabolism and Pharmacokinetics (DMPK), Boehringer Ingelheim. Dirk does research in Ophthalmology, Oncology focusing on DMPK and PK/PD. Their current project is 'Epigenetics'.

Research Interests

Papers共 53 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Supplementary Data Table 3 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Birgit Wilding,Lydia Woelflingseder,Anke Baum, Krzysztof Chylinski, Gintautas Vainorius, Neil Gibson,Irene C. Waizenegger,Daniel Gerlach, Martin Augsten,Fiona Spreitzer,Yukina Shirai,Masachika Ikegami, Sylvia Tilandyová,Dirk Scharn,Mark A. Pearson,Johannes Popow,Anna C. Obenauf,Noboru Yamamoto,Shunsuke Kondo,Frans L. Opdam,Annemarie Bruining,Shinji Kohsaka,Norbert Kraut,John V. Heymach,Flavio Solca,Ralph A. Neumüller

crossref（2025）

Cited0Views0Bibtex

Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Birgit Wilding,Lydia Woelflingseder,Anke Baum, Krzysztof Chylinski, Gintautas Vainorius, Neil Gibson,Irene C. Waizenegger,Daniel Gerlach, Martin Augsten,Fiona Spreitzer,Yukina Shirai,Masachika Ikegami, Sylvia Tilandyova,Dirk Scharn,Mark A. Pearson,Johannes Popow,Anna C. Obenauf,Noboru Yamamoto,Shunsuke Kondo,Frans L. Opdam,Annemarie Bruining,Shinji Kohsaka,Norbert Kraut,John V. Heymach,Flavio Solca,Ralph A. Neumueller

CANCER DISCOVERYno. 1 (2025): 119-138

Cited0Views0WOSBibtex

Elucidating the Novel Mechanism of Action of VVD-065, an Allosteric Molecular Glue for the KEAP1-CUL3 E3-ligase Complex That Promotes NRF2 Degradation in NRF2-activated Cancers

MOLECULAR CANCER THERAPEUTICSno. 12 (2023)

Cited0Views0Bibtex

Discovery of Potent and Selective HER2 Inhibitors with Efficacy Against HER2 Exon 20 Insertion-Driven Tumors, Which Preserve Wild-Type EGFR Signaling

Nature Cancer（2022）

Cited19Views0WOSNATUREBibtex

Novel EGFR WT Sparing, HER2 Selective Inhibitors for the Treatment of HER2 Exon 20 Insertion Driven Tumors Address a Clear Unmet Medical Need

Ralph A. Neumueller,Birgit Wilding,Dirk Scharn, Dietrich Boese,Valeria Santoro,Daniel Gerlach,Peter Ettmayer,Thomas Gerstberger,Julian Fuchs,Matthias Treu,Stephan Zahn,Anke Baum,Paolo Chetta,Mark Pearson,Darryl B. McConnell,Norbert Kraut,Flavio Solca

CANCER RESEARCH（2021）

Cited1Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn